 Sirolimus
"Sirolimus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
| Descriptor ID |
D020123
|
| MeSH Number(s) |
D02.540.505.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sirolimus".
Below are MeSH descriptors whose meaning is more specific than "Sirolimus".
This graph shows the total number of publications written about "Sirolimus" by people in this website by year, and whether "Sirolimus" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 0 | 3 | 3 | | 1993 | 0 | 2 | 2 | | 1994 | 0 | 2 | 2 | | 1995 | 0 | 1 | 1 | | 1996 | 0 | 3 | 3 | | 1999 | 0 | 1 | 1 | | 2000 | 2 | 3 | 5 | | 2001 | 2 | 2 | 4 | | 2002 | 2 | 3 | 5 | | 2003 | 7 | 7 | 14 | | 2004 | 10 | 12 | 22 | | 2005 | 14 | 7 | 21 | | 2006 | 16 | 3 | 19 | | 2007 | 17 | 7 | 24 | | 2008 | 8 | 14 | 22 | | 2009 | 20 | 10 | 30 | | 2010 | 15 | 19 | 34 | | 2011 | 23 | 12 | 35 | | 2012 | 15 | 18 | 33 | | 2013 | 17 | 18 | 35 | | 2014 | 21 | 17 | 38 | | 2015 | 13 | 14 | 27 | | 2016 | 4 | 6 | 10 | | 2017 | 2 | 9 | 11 | | 2018 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Sirolimus" by people in Profiles.
-
Zhu PJ, Chen CJ, Mays J, Stoica L, Costa-Mattioli M. mTORC2, but not mTORC1, is required for hippocampal mGluR-LTD and associated behaviors. Nat Neurosci. 2018 06; 21(6):799-802.
-
Bélanger C, Bérubé-Simard FA, Leduc E, Bernas G, Campeau PM, Lalani SR, Martin DM, Bielas S, Moccia A, Srivastava A, Silversides DW, Pilon N. Dysregulation of cotranscriptional alternative splicing underlies CHARGE syndrome. Proc Natl Acad Sci U S A. 2018 01 23; 115(4):E620-E629.
-
Tarek N, Hayes-Jordan A, Salvador L, McAleer MF, Herzog CE, Huh WW. Recurrent desmoplastic small round cell tumor responding to an mTOR inhibitor containing regimen. Pediatr Blood Cancer. 2018 Jan; 65(1).
-
Moreno-Smith M, Lakoma A, Chen Z, Tao L, Scorsone KA, Schild L, Aviles-Padilla K, Nikzad R, Zhang Y, Chakraborty R, Molenaar JJ, Vasudevan SA, Sheehan V, Kim ES, Paust S, Shohet JM, Barbieri E. p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. Clin Cancer Res. 2017 Nov 01; 23(21):6629-6639.
-
Warren D, Diaz L, Levy M. Diffuse Hepatic Hemangiomas Successfully Treated Using Sirolimus and High-Dose Propranolol. Pediatr Dermatol. 2017 Sep; 34(5):e286-e287.
-
Janku F. Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. Cancer Treat Rev. 2017 Sep; 59:93-101.
-
Valdez BC, Hassan M, Andersson BS. Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions. Exp Hematol. 2017 08; 52:65-71.
-
Logan SA, Thyparampil PJ, Yen MT. Immunosuppressant-Related Lower Eyelid Edema in Transplant Patients. Ophthalmic Plast Reconstr Surg. 2017 May/Jun; 33(3S Suppl 1):S58-S60.
-
Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.
-
Rheingold SR, Tasian SK, Whitlock JA, Teachey DT, Borowitz MJ, Liu X, Minard CG, Fox E, Weigel BJ, Blaney SM. A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114). Br J Haematol. 2017 05; 177(3):467-474.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|